Trial in progress: A phase 3 randomized study of low-dose intralesional cemiplimab versus primary surgery for patients with early-stage cutaneous squamous cell carcinoma (CLEAR CSCC).

Authors: Michael Robert Migden, Sherrif Ibrahim, John Strasswimmer, Nathalie Zeitouni, Suk-Young Yoo, Frank A. Seebach, Israel Lowy, Mihaela C. Cristea, Matthew G. Fury

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps9612

Source: Full article

---

Abstract

TPS9612